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AbstrACt
Objectives The aims of this study were (1) to document 
the clinical condition of patients considered to be in the 
last 2 weeks of life and (2) to compare patients who did or 
did not survive for 72 hours.
Design A prospective observational study.
setting Two sites in London, UK (a hospice and a hospital 
palliative care team).
Participants Any inpatient, over 18 years old, English 
speaking, who was identified by the palliative care team as 
at risk of dying within the next 2 weeks was eligible.
Outcome measures Prognostic signs and symptoms 
were documented at a one off assessment and patients 
were followed up 7 days later to determine whether or not 
they had died.
results Fifty participants were recruited and 24/50 (48%) 
died within 72 hours of assessment. The most prevalent 
prognostic features observed were a decrease in oral 
food intake (60%) and a rapid decline of the participant’s 
global health status (56%). Participants who died within 
72 hours had a lower level of consciousness and had more 
care needs than those who lived longer. A large portion 
of data was unavailable, particularly that relating to the 
psychological and spiritual well-being of the patient, due to 
the decreased consciousness of the patient.
Conclusions The prevalence of prognostic signs and 
symptoms in the final days of life has been documented 
between those predicted to die and those who did not. 
How doctors make decisions with missing information is 
an area for future research, in addition to understanding 
the best way to use the available information to make 
more accurate predictions.
bACkgrOunD
Caring for a dying person is a core skill 
required of every doctor and healthcare 
professional.1 Part of this competency is 
to be able to recognise when the person is 
dying in order to facilitate a ‘good death’.2 
Recognising this terminal phase can enable 
the dying person to spend time with their 
loved ones in a location of their choice. The 
‘More Care; Less Pathway’ report3 alongside 
other research4 5 has highlighted that medical 
teams are not very accurate at recognising 
when patients are (or are not) imminently 
dying.
One way to improve this skill is to teach 
staff which signs and symptoms are most prev-
alent at the end of life. There are a number 
of reports from organisations such as The 
National Council for Palliative Care and 
the National Institute for Health and Care 
Excellence, which present narrative summa-
ries of the symptoms and signs that are most 
common during the last few days of life.6–11 
Previous research and systematic reviews have 
identified which signs and symptoms are prev-
alent among patients dying from cancer12–18 
or other diseases.19–27 Interviews or surveys 
with health professionals have also been 
used to determine which signs or symptoms 
staff believe are most indicative of imminent 
death.28–31 From the literature, it appears that 
common signs include changes in breathing 
patterns, altered consciousness, agitation, 
changes to the appearance of the skin, incon-
tinence or reduced urinary output, changes 
in functional ability and social withdrawal. 
Common symptoms include tiredness, 
reduced appetite and confusion.
Despite this body of evidence regarding 
signs and symptoms, these findings have 
not translated in to practice; medical teams 
continue to be inaccurate at recognising 
imminent death.3 It has been highlighted 
from recent reports that evidence regarding 
strengths and limitations of this study
 ► An observational study that prospectively docu-
mented prognostic signs and symptoms in relation 
to survival of 72 hours.
 ► Highlights the prevalence of missing data in palli-
ative care.
 ► The results reflect only the participants that were re-
cruited as part of this study, those who were referred 
to specialist palliative care. Other results might have 
been prevalent in a different population.
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the clinical presentation of people who were predicted 
to die, but subsequently did not, is lacking.3 4 Finally, 
findings from palliative care research highlight the high 
degree of missing or unavailable data.32 If the common 
signs and symptoms identified from previous research are 
not available, or are missing, in the final days of life, then 
just how is death recognised?
This study was the first stage of a larger study investi-
gating the recognition of dying.33 The objectives of this 
reasearch are:
1. To prospectively document the clinical condition of 
patients considered to be in the last 2 weeks of life.
2. To compare the clinical condition of patients who did 
or did not survive for 72 hours.
MethODs
A prospective observational study of patients referred to 
specialist palliative care. This study follows the Strength-
ening the Reporting of OBbservational Studies in 
Epidemiology reporting guidelines (see online supple-
mentary file 1). The original protocol for the study is 
in online supplementary file 2.
settings
Recruitment took place at two palliative care services in 
London, UK (a hospice and a hospital) between January 
2015 and October 2015.
Participants
All inpatient referrals to the palliative care team were 
screened by their respective clinical teams for eligibility. 
Palliative care was selected as the specialty to mitigate risk 
that the death would be sudden or unexpected.
Inclusion criteria
1. 18 years old and over.
2. Identified by the palliative care team as likely to die in 
the next 2 weeks.
3. The patient or family could speak enough English for 
the researcher to discuss the study.
Exclusion criteria
1. Assessed as not suitable to approach by the clinical 
team (ie, discussing the research would cause too 
much distress)
2. Lacked capacity and no personal consultee (family 
member) available
3. Refused to participate, either verbally or through an 
advance directive
sample size
This study formed part of a programme of research 
designed to devise a test for assessing clinicians’ prog-
nostic accuracy.34 For the purpose of devising a prog-
nostic test,33 it was necessary to obtain data from at least 
20 patients (10 of whom died and 10 of whom survived 
for 72 hours). To ensure that at least 20 cases were suit-
able for inclusion in the study to devise a prognostic test, 
we aimed to recruit approximately 50 cases in total. The 
final sample was determined by the number of inpatient 
referrals who were eligible and willing to participate 
during the study recruitment period.
Patient and public involvement
Feedback on the protocol was sought from a consumer 
research panel (South West London Cancer Research 
Group). The suggestions from the group were reflected 
in the study protocol, specifically the study information 
sheets.
ethical issues
Recruiting people who are at the ends of their lives pres-
ents ethical challenges. In both the hospice and hospital, 
this may have been the first time that the individual had 
been referred to palliative care. An inclusion criterion for 
the study was that the patient was considered to be likely 
to die within 2 weeks. This information had the potential 
to cause upset to both the family and the patient, unless 
it was handled sensitively by clinical staff. We addressed 
these concerns by allowing clinical teams to exclude 
potentially eligible patients if they judged that discussing 
the research would cause too much distress. Since this 
study did not require a consecutive series of patients, it 
was not felt to affect the integrity of the study to allow clin-
ical teams the discretion to operate this form of research 
‘gate-keeping’.
Consent procedure
We expected a high number of participants to be uncon-
scious or unresponsive and, as a consequence, to lack 
capacity. We adhered to the Mental Capacity Act35 guide-
lines for recruiting patients without capacity. We also 
mirrored the approach taken in a similar study that had 
recruited patients admitted to the acute setting.36
If the clinician felt that involvement in the study would 
not cause distress, the clinician asked the patient, or their 
family member, if they wished to meet the researcher to 
discuss taking part in the study. If they agreed to this, 
the researcher briefed the patient and/or their family 
member about the research and obtained either informed 
consent or personal consultee agreement.
Due to the time sensitive nature of the research, there 
was no enforced delay between informing the patient 
about the study and seeking consent to participate. Each 
patient who entered the study was informed that they 
could withdraw at any time, without reason and without 
consequence to their care. It was possible to gain tele-
phone advice from a personal consultee should they not 
live locally. If telephone advice was obtained, an infor-
mation sheet and a ‘documentation of advice’ form were 
posted to the family member with a return address. If the 
form was not returned, or was returned incomplete, the 
data pertaining to that patient were removed from the 
database and destroyed (see online supplementary file 
3).
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Procedure
All participants, on entering the study, underwent a single 
observer-rated assessment of key prognostic features (see 
below), medications and overall condition. Information 
regarding their medical history, their reason for admis-
sion and their demographic details were extracted from 
the medical notes. Data regarding signs and symptoms 
over the last 24 hours were obtained from direct observa-
tion of, or discussion with, the patient or from discussing 
their care with medical or nursing staff.
Measures
We collected data on prognostic variables that had 
previously been identified from the literature. We used 
validated measures to record agitation or sedation, func-
tional ability and comorbidities.
Richmond Agitation Sedation Scale
This scale assesses patients’ level of agitation or sedation. 
The scale ranges from +4 (combative) to −5 (unarous-
able). The Richmond Agitation Sedation Scale (RASS) 
has high validity and reliability within a hospital setting.37 
This measure has previously been used in mortality 
research.38 It distinguishes in greater detail than other 
scales the different levels of sedation.
Palliative Performance Scale
This scale is used to assess palliative care patients’ func-
tional ability.39 It consists of five domains: Ambulation, 
Activity and Evidence of Disease, Self-Care, Intake and 
Conscious Level. Scores can range between 10% (fully 
dependent) and 100% (fully independent). A decrease in 
the patient’s functional ability has been shown to predict 
death.40
Charlson Comorbidity Index score
This score summarises the severity of chronic comor-
bidities. It includes 19 diseases that are weighted by 
their association with mortality. Higher scores reflect a 
greater number and/or severity of comorbidities.41 This 
was obtained from the patient’s medical records. The 
Charlson Comorbidity Index (CCI) has been shown to 
predict short and long term mortality.42
Clinical signs and symptoms
As we wanted to provide a rich description of the patients 
who were potentially in the final days of life, we included 
all symptoms and signs that have previously been iden-
tified as being potentially predictive of the dying 
phase12 14–16 19–22 24–26 28–30:
 ► Respiration (rate and character)
 ► Blood circulation (pulse rate, blood pressure, periph-
eral perfusion, cyanosis)
 ► Physical condition (performance status, mobility)
 ► Skin integrity
 ► Excretion (continence, presence of indwelling 
catheter)
 ► Oral intake
 ► Pain
 ► Consciousness (level of sedation or agitation)
 ► Psychological/Spiritual condition
 ► Other
The full list of clinical signs and symptoms recorded is 
shown in online supplementary file 4.
We reported on the prevalence of missing data, which 
are common in palliative care studies.32 For example, 
for several self-reported symptoms, it was not possible 
to obtain an answer for patients who were unconscious, 
unless the patient’s family members or attending nurse 
were able to act as a proxy provider of information. This 
was particularly common when assessing the psycholog-
ical state of the participant. Similarly, when a patient had 
a urinary catheter or a stoma, it was not possible to deter-
mine continence level.
Main outcome
The main outcomes of interest were the characteristics 
of patients who did and did not die within 72 hours of 
assessment. Each participant was followed up 7 days after 
the day of observation. During this time, if the participant 
died, the date of death was recorded.
Analysis
The purpose of this study was to describe the presence or 
absence of key prognostic features in patients who were or 
were not dying, under the care of palliative care services, 
rather than to test specific hypotheses about differences 
between subgroups of participants. Therefore, to avoid 
overinterpretation of our data, no statistical tests have 
been performed to assess for such differences. Results 
have been summarised using descriptive statistics.
results
recruitment
In total, 60 patients were approached to participate in 
this study (see figure 1). Ten were not included because: 
they had died before the researcher could see them 
(n=5); they had declined to participate (n=3); or they 
had no personal consultee available (n=2). Therefore, 50 
Figure 1 Recruitment flowchart.
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patients were included in this analysis, of whom 24 (48%) 
died within 72 hours of assessment.
Participant characteristics
The characteristics of participants recruited are presented 
in table 1.
By site
The patients in hospital were older compared with the 
hospice (mean 76 years, SD 16 vs 64, SD 14) with a higher 
prevalence of non-cancer diagnoses (48% vs 11%). They 
had fewer serious comorbidities than the patients from 
the hospice (CCI mean 5.0, SD 2.1 vs 6.2, SD 1.8) and 
more patients died within 72 hours within the hospital 
(65% vs 21%).
By survival
Slightly more men than women died within 72 hours 
(58% vs 42%). The mean age of patients who died within 
72 hours was higher (78 years, SD 13) than those who did 
not (67, SD 18). There was little difference in comorbid-
ities between those who died within 72 hours (CCI mean 
5.2, SD 2.2) and those who did not (5.7, SD 1.9). Of those 
who died within 72 hours, 50% had cancer, and 50% did 
not.
Palliative Performance Scale
The Palliative Performance Status (PPS) was assessed for 
every participant. The PPS scores ranged between 10% 
and 70%, with a median of 30% (IQR 10, 40). The partic-
ipants who died within 72 hours had a median PPS score 
of 10% (IQR 10, 30). Participants who survived beyond 
72 hours had a median PPS score of 40% (IQR 20, 50).
Richmond Agitation Sedation Scale
Scores for the RASS ranged between +2 and −5. The 
median score for the total population was −1 (IQR −4, 0). 
The distribution of scores was bimodal; 12 patients (24%) 
had a score of 0 and nine (18%) had a score of −5. The 
participants who died within 72 hours of assessment were 
either deeply unconscious (n=15, 62.5% scored either −4 
or −5) or were agitated (n=5, 20% scored +1 or +2) with 
a median score of −4 (IQR −4.5,–0.5). The participants 
who did not die within 72 hours were largely calm with 
mild agitation or sedation (n=18, 70% scored between −1 
and +1) and a median score of −0.5 (IQR −2, 0).
Clinical signs and symptoms prevalence
Table 2 details the prevalence of the signs and symp-
toms noted during the study. Overall, the most prevalent 
features observed were a decrease in oral food intake 
(60%) and a rapid decline of the participant’s global 
health status (56%).
Participants who died within 72 hours were more 
frequently noted to have: a rapid decline of their global 
condition (75% vs 38%); decreased urine production 
(71% vs 23%); more concentrated urine (67% vs 31%); 
incontinence of faeces (71% vs 19%); noisy respiratory 
secretions (54% vs 15%); Cheyne-Stoke breathing (17% 
vs 4%); peripheral cyanosis (21% vs 4%); and refusal of 
food (21% vs 4%). There were two symptoms that were 
only seen in participants who died within 72 hours: respi-
ration with mandibular movement (n=2; 8%) and pulse-
lessness of the radial artery (n=2; 8%). Participants who 
survived longer than 72 hours were more frequently noted 
to have a loss of appetite (69% vs 25%) and pain (42% vs 
4%) and were more likely to express anxiety or fear (54% 
vs 17%) and were more accepting of their death (38% vs 
8%); however, these data were more likely to be missing 
for patients who survived less than 72 hours.
Missing data
As shown in table 2, there were some prognostic features 
for which almost half of the data were recorded as missing. 
In general, the proportion of missing data was higher in 
patients who died within 72 hours compared with those 
who survived. Measures such as the physical condition, 
oral intake, psychological well-being and whether they 
were experiencing shortness of breath were often not 
available either because there was no meaningful answer 
(ie, the patient had a catheter/stoma or the patient was 
not alert enough to respond, with no proxy measure avail-
able) or the information was not recorded. The aim of 
this study was to document all previously identified prog-
nostic features in patients who were referred to specialist 
palliative care teams. While the diminished consciousness 
of the patient, which is an evidence-based prognostic 
indicator in its own right, could have limited the ability 
to collect some of this data; the fact that data relating to 
some of these features were frequently missing in those 
who died within 72 hours is a relevant and novel finding 
which has implications for clinical practice.
Table 1 Participant characteristics
Demographics Total
n (%)
Participants 50 (100)
Gender
  Male 30 (60)
  Female 20 (40)
Age (mean, SD) 72.0 (16.60)
Ethnicity
  White British 36 (72)
  Other 14 (28)
Cancer diagnosis?
  Yes 33 (66)
  No 17 (34)
Charlson score (mean, SD) 5.43 (2.05)
Length of survival
  Less than 72 hours 24 (48)
  More than 72 hours 26 (52)
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Table 2 Prevalence of key prognostic features over the previous 24 hours in patients who did or did not die imminently
Died <72 hours (n=24) Died >72 hours (n=26)
Present Absent Missing Present Absent Missing
n (%) n (%)
Respiration
  Short of breath 2 (8) 5 (21) 17 (71) 8 (31) 12 (46) 6 (23)
  Noisy respiratory secretions 13 (54) 11 (46) 0 (0) 4 (15) 22 (85) 0 (0)
  Cheyne-Stokes type breathing 4 (17) 20 (83) 0 (0) 1 (4) 25 (96) 0 (0)
  Abdominal swelling 4 (17) 20 (83) 0 (0) 9 (35) 17 (65) 0 (0)
  Respiration with mandibular movement 2 (8) 22 (92) 0 (0) 0 (0) 26 (100) 0 (0)
Blood circulation
  Pulselessness of the radial artery 2 (8) 13 (54) 9 (38) 0 (0) 24 (92) 2 (8)
  Peripheral cyanosis 5 (21) 17 (71) 2 (8) 1 (4) 25 (96) 0 (0)
  Nose becomes more ‘pointed’ 0 (0) 21 (88) 3 (13) 0 (0) 26 (100) 0 (0)
  Change in skin condition (moisture, colour, 
temperature)
8 (33) 16 (67) 0 (0) 8 (31) 18 (69) 0 (0)
Physical condition
  Extreme tiredness 4 (17) 4 (17) 16 (67) 11 (42) 9 (35) 6 (23)
  Insomnia 1 (4) 7 (29) 16 (67) 6 (23) 14 (54) 6 (23)
  Surges of energy 0 (0) 8 (33) 16 (67) 2 (8) 18 (69) 6 (23)
  Rapid decline of global condition 18 (75) 6 (25) 0 (0) 10 (38) 16 (62) 0 (0)
Skin integrity
  Wounds, ulcers or sores on the skin 6 (25) 18 (75) 0 (0) 7 (27) 19 (73) 0 (0)
Excretion
  Catheter 16 (67) 8 (33) 0 (0) 11 (42) 15 (58) 0 (0)
  Stoma 1 (4) 23 (96) 0 (0) 6 (23) 20 (77) 0 (0)
  Concentrated urine 16 (67) 7 (29) 1 (4) 8 (31) 12 (46) 6 (23)
  Incontinence (urinary) 5 (21) 3 (13) 16 (67) 5 (19) 10 (38) 11 (42)
  Incontinence (faecal) 17 (71) 6 (25) 1 (4) 5 (19) 14 (54) 7 (27)
  Vomiting 3 (13) 21 (88) 0 (0) 9 (35) 17 (65) 0 (0)
  Altered defecation—diarrhoea 4 (17) 19 (79) 1 (4) 6 (23) 19 (73) 1 (4)
  Altered defecation – constipation 9 (38) 14 (58) 1 (4) 10 (38) 15 (58) 1 (4)
  Decreased production of urine 17 (71) 5 (21) 2 (8) 6 (23) 13 (50) 7 (27)
Oral intake
  Decreased eating 13 (54) 1 (4) 10 (42) 17 (65) 4 (15) 5 (19)
  Decreased drinking 13 (54) 2 (8) 9 (38) 13 (50) 8 (31) 5 (19)
  Refusing food 5 (21) 5 (21) 14 (58) 1 (4) 18 (69) 7 (27)
  Swallowing difficulty 4 (17) 4 (17) 16 (67) 8 (31) 13 (50) 5 (19)
  Loss of appetite 6 (25) 1 (4) 17 (71) 18 (69) 2 (8) 6 (23)
Pain
  Patient reported pain 1 (4) 8 (33) 15 (63) 11 (42) 10 (38) 5 (19)
  Clinician reported pain 3 (13) 21 (88) 0 (0) 10 (38) 16 (62) 0 (0)
  Pain is less responsive to treatment 1 (4) 20 (83) 3 (13) 1 (4) 23 (88) 2 (8)
Psychological condition/spiritual
  Confusion 6 (25) 2 (8) 16 (67) 7 (27) 11 (42) 8 (31)
  Delirium 2 (8) 6 (25) 16 (67) 1 (4) 18 (69) 7 (27)
  Anxiety/fear 4 (17) 2 (8) 18 (75) 14 (54) 5 (19) 7 (27)
Continued
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DisCussiOn
This study described the presence or absence of key 
prognostic features in palliative care patients who were 
thought to be in the last 2 weeks of life and who did or did 
not die within 72 hours of assessment.
In patients thought to be in the last 2 weeks of life, there 
was a reduction in physical ability, as measured by the 
palliative performance scale. Three symptoms affected 
at least half of the patients: reduced oral intake, a rapid 
decline in condition and a change in excretions. This 
result is slightly inconsistent with other studies that have 
suggested that other symptoms such as fatigue and mental 
haziness are more prevalent in the last weeks of life.43–45
Different symptoms were prevalent in patients who 
died within 72 hours and in those who survived for longer. 
Patients who died within 72 hours had a lower palliative 
performance score and experienced either more agitation 
or more sedation than patients who survived longer than 
72 hours. Some symptoms were more prevalent in patients 
who died imminently, such as a rapid decline in global 
condition, decreased urine output, increased anxiety, 
incontinence, noisy respiratory secretions, Cheyne-Stoke 
breathing and peripheral cyanosis. The small sample 
size of this study means that the estimates of the preva-
lence of particular symptoms should only be regarded 
as tentative. Two symptoms, although uncommon, were 
only noticed in patients who died imminently: respira-
tion with mandibular movement and pulselessness of 
the radial artery. These symptoms have been previously 
suggested to predict imminent death.12 13 16 One previous 
study reported that observations of the patient, such as 
heart rate and oxygen saturation, may also be predictive 
of imminent death but that for a large portion of patients, 
these vital signs were within a normal range in the last 
days of life.17 Most of the patients in our study did not 
have routine observations undertaken and so no such 
data were available.
This reiterates the importance of further research within 
a palliative care context particularly in the final days of 
life and about how to make prognostic decisions in the 
context of incomplete data.32 A large volume of data was 
recorded as missing for patients who died within 72 hours 
in this study. This is an interesting finding and highlights 
the complicated landscape in which the medical team 
are asked to make predictions about imminent death 
based on information that is not always possible to obtain 
about the patient. The prevalence of prognostic factors 
in this study demonstrates the large amount of potential 
prognostic information that medical teams have to weigh 
up when making a decision about end of life care. Further 
research is required to determine how these decisions are 
made in practice.
strengths and weaknesses
This study is one of the first, to the authors knowledge, to 
prospectively observe prognostic signs and symptoms in 
the final days of life. However, these data are only taken 
from two london specialist palliative care teams. If a 
different population had been recruited, it is possible that 
other signs and symptoms may have been more prevalent. 
For example, patients who are not referred to specialist 
palliative care teams might present differently towards the 
end of life. This is an area for further research. This study 
was not designed to demonstrate an association between 
the prevalence of symptoms at the end of life and death 
within days, and any apparent differences between groups 
need further confirmation in a comparative study.
COnClusiOn
This study lends support to the usefulness of certain 
key prognostic features for predicting immnent death 
in palliative care inpatients. Further work is required to 
understand how clinicans should best integrate these 
prognostic features, while taking into account the volume 
of missing information, to refine their prognostic esti-
mates of imminent death.
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